The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - MedAssessment; SynDevRx
Leadership - MedAssessment
Consulting or Advisory Role - SynDevRx
Research Funding - SynDevRx
The Amelia-1 study: A phase 1b/2 trial of evexomostat (SDX-7320) plus fulvestrant and alpelisib in patients with advanced breast cancer at risk for alpelisib-induced hyperglycemia.
 
Peter Cornelius
Employment - SynDevRx
Stock and Other Ownership Interests - SynDevRx
Research Funding - SynDevRx
Patents, Royalties, Other Intellectual Property - SynDevRx
Travel, Accommodations, Expenses - SynDevRx
Other Relationship - SynDevRx
 
Neal Salomon
Consulting or Advisory Role - SynDevRx
Research Funding - SynDevRx
 
David Browning
Consulting or Advisory Role - SynDevRx
Research Funding - SynDevRx
Travel, Accommodations, Expenses - SynDevRx
 
Benjamin Mayes
Employment - SynDevRx
Stock and Other Ownership Interests - SynDevRx
Research Funding - SynDevRx
Patents, Royalties, Other Intellectual Property - SynDevRx
Travel, Accommodations, Expenses - SynDevRx
 
Pierre Dufour
Employment - SynDevRx
Stock and Other Ownership Interests - SynDevRx
Research Funding - SynDevRx
 
Margaret S. Fletcher
No Relationships to Disclose
 
James Shanahan
Employment - SynDevRx
Leadership - SynDevRx
Stock and Other Ownership Interests - SynDevRx
Research Funding - SynDevRx
Patents, Royalties, Other Intellectual Property - SynDevRx
Travel, Accommodations, Expenses - SynDevRx
Other Relationship - SynDevRx (I)
 
Bradley Carver
Employment - SynDevRx
Leadership - SynDevRx
Stock and Other Ownership Interests - SynDevRx
Research Funding - SynDevRx
Patents, Royalties, Other Intellectual Property - SynDevRx
Travel, Accommodations, Expenses - SynDevRx
Other Relationship - SynDevRx (I)
 
Hope S. Rugo
Consulting or Advisory Role - Blueprint Medicines; Napo Pharmaceuticals; Puma Biotechnology; Scorpion Therapeutics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Pionyr (Inst); Sermonix Pharmaceuticals (Inst); Taiho Oncology (Inst); Veru (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Merck